PA
CYCN icon

Perennial Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Perennial Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-90
Closed -$7K – 122
2021
Q2 		$7K Hold
90
– – ﹤0.01% 253
2021
Q1 		$5K Hold
90
– – ﹤0.01% 257
2020
Q4 		$5K Buy
+90
New +$6.14K ﹤0.01% 223
2020
Q3 		– Sell
-90
Closed -$11K – 106
2020
Q2 		$11K Buy
+90
New +$7.53K ﹤0.01% 186

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perennial Advisors's CYCN Position: Q3 2021 in Review

Perennial Advisors sold out of Cyclerion Therapeutics (CYCN) in Q3 2021, closing a stake of 90 shares — an estimated $7K sold.

Perennial Advisors first reported a position in CYCN in Q2 2020 and held it in 4 quarters. The position peaked at $11K in Q2 2020. 61 funds tracked by Wall St. Rank hold CYCN as of Q3 2021.

  • Perennial Advisors reported no remaining Cyclerion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Perennial Advisors sold 90 Cyclerion Therapeutics shares in Q3 2021, an estimated $7K.
  • Perennial Advisors first reported a position in Cyclerion Therapeutics in Q2 2020 and held it in 4 quarters.
  • Perennial Advisors's Cyclerion Therapeutics position peaked at $11K in Q2 2020.
  • 61 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2021.

Based on Perennial Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.